October 17, 2019
NeuClone starts dosing Stelara biosimilar candidate, NeuLara, in a Phase I clinical trial
NeuClone starts dosing NeuLara ustekinumab the first patients, a Johnson and Johnson’s Stelara biosimilar candidate, in a Phase I clinical…